Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
This is a multicentric, phase II and open label study.75 patients are expected to be randomized in 35 centers. The main objective is to assess the efficacy and safety of Afatinib -cetuximab combo versus cetuximab alone in treatment of patients with refractory wtKRAS metastatic colorectal cancer.
Epistemonikos ID: efa8f97e09fb312c3f22ae6b315df8915553eb6a
First added on: May 11, 2024